Related Experiment Video

Updated: May 23, 2026

Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
07:32

Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography

Published on: March 30, 2022

Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease

Alexandros Briasoulis1, Dimitris Tousoulis, Nikolaos Papageorgiou

  • 11st Cardiology Unit, Hippokration Hospital, Athens University Medical School, Greece. alexbriasoulis@gmail.com

Current Topics in Medicinal Chemistry
|April 24, 2012
PubMed

Insights

Matrix metalloproteinases (MMPs) regulate extracellular matrix. Inhibiting MMPs offers therapeutic potential for cardiovascular diseases like atherosclerosis by restoring MMP-TIMP balance.

Area of Science:

  • Cardiovascular Biology
  • Enzymology
  • Pharmacology

Background:

  • Matrix metalloproteinases (MMPs) are key enzymes in extracellular matrix remodeling and degradation.
  • Their activity is tightly regulated by transcription, zymogen activation, and tissue inhibitors of metalloproteinases (TIMPs).
  • Dysregulated MMP activity is linked to cardiovascular pathologies, including atherosclerosis, coronary artery disease, and heart failure.

Purpose of the Study:

  • To review the pathological roles of MMPs and TIMPs in cardiovascular diseases.
  • To explore MMPs as therapeutic targets for vascular pathology.
  • To discuss pharmacological strategies for MMP inhibition.

Main Methods:

  • Literature review of MMPs and TIMPs in cardiovascular disease.
  • Analysis of MMPs' role in vascular remodeling and plaque instability.
  • Examination of therapeutic interventions targeting MMPs.

Main Results:

  • Altered MMP regulation contributes to atherosclerotic plaque development and progression.
  • MMPs and TIMPs are involved in vascular remodeling post-myocardial infarction.
  • Excessive MMP activity correlates with atherosclerotic lesion advancement.

Conclusions:

  • Restoring the balance between MMPs and TIMPs is a promising therapeutic strategy.
  • Pharmacological inhibition of MMPs holds potential for treating cardiovascular diseases.
  • Targeting MMPs could modify vascular pathology and improve outcomes.

More Related Videos

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

Measuring Global Cellular Matrix Metalloproteinase and Metabolic Activity in 3D Hydrogels07:39

Measuring Global Cellular Matrix Metalloproteinase and Metabolic Activity in 3D Hydrogels

Published on: January 22, 2019

Related Concept Videos

Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...